“A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection” and “Long-term Outcome Reporting in Older Kidney Transplant Recipients and the Limitations of Conventional Survival Metrics
2024-11-21 23:00 - 2024-11-22 00:00 UTC
- https://learn.houstonmethodist.org/2024-transplant-journal-club/content/%E2%80%9C-randomized-phase-2-trial-felzartamab-antibody-mediated-rejection%E2%80%9D-and-%E2%80%9Clong-term-outcome
